← All trials
NCT00685828
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2001
- Primary completion
- Feb 1, 2002
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 946
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- University of MilanStudy chair
- Lund UniversityStudy chair
- Italian Sarcoma GroupCollaborator
- Australasian Gastro-Intestinal Trials GroupCollaborator
- Scandinavian Sarcoma GroupCollaborator
- Erasmus University RotterdamStudy chair
- Peter MacCallum Cancer CentreStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.